Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol:
CD40
Name:
CD40 molecule
Location:
20q13.12
Locus Group:
protein-coding gene
Gene Type:
Protein Coding
Locus Type:
gene with protein product
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all
Clinical Studies
| NCT Number | Status | Brief Title | View |
|---|---|---|---|
| NCT00174057 | The Role of TSH Receptor PPAR-r IGF-1R IGF and Cytokines in Different Stages of GravesOphthalmopathy | View | |
| NCT00001145 | Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome | View | |
| NCT00958113 | Autoimmune Thyroid Disease Genetic Study | View | |
| NCT00982358 | Anti-Inflammatory Actions of Valsartan in Patients With Type 2 Diabetes Mellitus | View | |
| NCT01384565 | G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease | View | |
| NCT01604031 | Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells Lenalidomide | View | |
| NCT01812200 | Antithrombotic Triple Therapy in Humans | View | |
| NCT02763410 | Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation | View | |
| NCT00730314 | Unrelated Hematopoietic Stem Cell TransplantationHSCT for Genetic Diseases of Blood Cells | View | |
| NCT03605927 | CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease | View | |
| NCT05059431 | The Effect of Human Prostate Tissue on Platelet Activation | View | |
| NCT05217472 | An Efficacy and Safety Study of Injectable Ravagalimab to Assess Change in EULAR Sjogrens Syndrome Disease Activity Index ESSDAI in Adult Participants With Moderately to Severely Active Primary Sjogrens Syndrome pSS | View | |
| NCT00078520 | Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells | View | |
| NCT02140996 | Safety Study of Human MUC-1 Mucin-1 Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers | View | |
| NCT01103635 | Tremelimumab and CP-870893 in Patients With Metastatic Melanoma | View | |
| NCT01112137 | Effects of Clopidogrel on Blood Pressure | View | |
| NCT04130854 | INNATE Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | View | |
| NCT04337931 | A Study to Evaluate Sotigalimab APX005M in Subjects With Unresectable or Metastatic Melanoma | View | |
| NCT00020540 | Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer | View | |
| NCT00058786 | Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells | View | |
| NCT00525447 | Study of SGN-40 Lenalidomide and Dexamethasone in Patients With Multiple Myeloma | View | |
| NCT00445913 | Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression A Safety Study | View | |
| NCT03905525 | Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogrens Syndrome | View | |
| NCT00435916 | Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma | View | |
| NCT00504322 | Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene AdcuCD40L to Patients With Esophageal Carcinoma | View | |
| NCT00529503 | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | View | |
| NCT00108108 | Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia CLL That is Relapsed or Non-responsive to Prior Fludaribine Therapy | View | |
| NCT01561911 | A Phase I Study of the Chimeric Anti-CD40 Monoclonal Antibody ChiLob 74 to Treat Advanced Malignancies Refractory to Conventional Anti-cancer Treatment | View | |
| NCT00684242 | Lenalidomide Revlimid for the Treatment of Refractory Cancer Pain | View | |
| NCT01582399 | Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240 | View | |
| NCT00711191 | A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas | View | |
| NCT02225002 | Phase 1 Open-Label Dose-Escalation Study of CP-870893 in Patients With Solid Tumors | View | |
| NCT02320357 | Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous | View | |
| NCT01066559 | Improvement of Humoral Immune Response With Hemodialysis on BK-F Membrane Correlation to Soluble CD40 Clearing | View | |
| NCT01275209 | Study of HCD122 Lucatumumab and Bendamustine Combination Therapy in CD40 Rituximab-refractory Follicular Lymphoma | View | |
| NCT01780844 | A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients | View | |
| NCT01565681 | Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects | View | |
| NCT01585233 | A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis | View | |
| NCT05029999 | CD40 Agonist Flt3 Ligand and Chemotherapy in HER2 Negative Breast Cancer | View | |
| NCT03610516 | Safety Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis | View | |
| NCT02665416 | Study Evaluating the Safety Pharmacokinetics PK Pharmacodynamics PD and Therapeutic Activity of Selicrelumab RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors | View | |
| NCT00556699 | A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive Follicular and Marginal Zone B-Cell Non-Hodgkins Lymphoma | View | |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | View | |
| NCT04059588 | A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin | View | |
| NCT05484011 | A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | View | |
| NCT05585944 | Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 CT on the Risk of Immune Thrombocytopenic Purpura | View | |
| NCT02482168 | Study of the CD40 Agonistic Monoclonal Antibody APX005M | View | |
| NCT03719430 | APX005M and Doxorubicin in Advanced Sarcoma | View | |
| NCT02588443 | Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma | View | |
| NCT00006113 | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma | View | |
| NCT03852511 | First in Human Study of NG-350A an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody | View | |
| NCT03892525 | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma | View | |
| NCT02974192 | Neopterin Effects on Ischemic Stroke | View | |
| NCT04491084 | FLT3 Ligand CD40 Agonist Antibody and Stereotactic Radiotherapy | View | |
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma Including Ocular Melanoma | View | |
| NCT03123783 | CD40 Agonistic Antibody APX005M Sotigalimab in Combination With Nivolumab | View | |
| NCT04520711 | Hotspot TCR-T A Phase IIb Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells TCR-T | View | |
| NCT03214250 | Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma | View | |
| NCT03418480 | HARE-40 HPV Anti-CD40 RNA vaccinE | View | |
| NCT04635995 | Phase 1 Trial of LVGN7409 CD40 Agonist Antibody as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy | View | |
| NCT04842682 | Dose Escalation Trial of CD40HIVRIEnv Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers | View | |
| NCT06305286 | Safety Tolerability and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus T1D | View | |
| NCT03656562 | Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients | View | |
| NCT03781414 | Study of Efficacy Safety Tolerability Pharmacokinetic PK and Pharmacodynamic PD of an Anti-CD40 Monoclonal Antibody CFZ533 in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension | View | |
| NCT06440187 | Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11 | View | |
| NCT05098405 | First-in-human Safety and Tolerability of MP0317 in Patients With RelapsedRefractory Advanced Solid Tumors | View | |
| NCT05650918 | MesoPherMitazalimab-combination Therapy in Metastatic Pancreatic Disease REACtiVe-2 Trial | View | |
| NCT05693844 | Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in AdvancedMetastatic Solid Tumors | View | |
| NCT04322149 | Multiple Doses of AT-1501-A201 in Adults With ALS | View | |
| NCT06007092 | Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer | View | |
| NCT04541589 | Study of Safety and Tolerability of CFZ533 in Patients With Sjögrens Syndrome | View | |
| NCT04547777 | Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | View | |
| NCT04857138 | A Study to Evaluate Safety Pharmacokinetics and Anti-Tumor Activity of RO7300490 as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors | View | |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | View | |
| NCT02379741 | ADC-1013 First-in-Human Study | View | |
| NCT06347705 | A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer | View | |
| NCT04993677 | A Study of SEA-CD40 Given With Other Drugs in Cancers | View | |
| NCT05126472 | Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment | View | |
| NCT05152212 | Study of LVGN7409 CD40 Agonist Antibody in Locally Advanced Metastatic or RecurrentRefractory Malignancy | View | |
| NCT05349890 | Personalized TCR-T Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells TCR-T | View | |
| NCT00058799 | Treating High Risk Leukemia With CD40 Ligand IL-2 Gene Modified Tumor Vaccine | View | |
| NCT00840931 | Immunotherapy Using Lenalidomide Bystander Vaccine in High Risk Myelodysplastic Syndrome MDS | View | |
| NCT05849480 | A Study of CDX-1140 a CD40 Agonist in Combination With Capecitabine and Oxaliplatin CAPOX and Keytruda in Subjects With Biliary Tract Carcinoma BTC | View | |
| NCT01222039 | Multicenter Clinical Trial for the Evaluation of Mesenchymal Stem Cells From Adipose Tissue in Patients With Chronic Graft Versus Host Disease | View | |
| NCT06205849 | Intra-tumoral Mitazalimab CD40 Antibody With Irreversible Electroporation IRE in Locally Advanced Pancreas Cancer | View | |
| NCT06459869 | NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer | View | |
| NCT00020670 | Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia | View | |
| NCT00231166 | Safety Efficacy Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma | View | |
| NCT00008749 | Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus | View | |
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | View | |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkins or Hodgkins Lymphoma Who Have Progressed After at Least Two Prior Therapies | View | |
| NCT04080453 | Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock | View | |
| NCT00787137 | Single Dose PG102 in Patients With Active Psoriatic Arthritis | View | |
| NCT06159621 | CD40 Agonist and PD-1 Inhibitor in HNSCC | View | |
| NCT00053391 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | View | |
| NCT05165433 | Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours FORTIFY | View | |
| NCT02193360 | Pilot Study of FFP104 Dose Escalation in PBC Subjects | View | |
| NCT02217410 | CCFZ533X2201 - PoC Study in de Novo Renal Transplantation | View | |
| NCT03165994 | APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers | View | |
| NCT02829099 | A Study of Safety Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors | View | |
| NCT00079716 | Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma | View | |
| NCT00224354 | Lymphocytic B-Leukemia B-CLL wHuman IL-2 Gene Modified Human CD40 Ligand-Expressing Autologous Tumor Cells | View | |
| NCT00266513 | Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States | View | |
| NCT02304393 | A Study of Selicrelumab RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced andor Metastatic Solid Tumors | View | |
| NCT00283101 | A Safety Study in Patients With Chronic Lymphocytic Leukemia | View | |
| NCT00103779 | A Safety Study of SGN-40 in Patients With Non-Hodgkins Lymphoma | View | |
| NCT00328887 | Safety Study on the Transfer of the CD40 Ligand Gene AdcuCD40L to Patients With Esophageal Carcinoma | View | |
| NCT00458679 | Treatment of B-Chronic Lymphocytic Leukemia B-CLL With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells | View | |
| NCT00655837 | Trial to Define the Safety and Tolerability of SGN-40 Rituximab and Gemcitabine in Patients With DLBCL | View | |
| NCT00664898 | A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma | View | |
| NCT02706353 | APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | View | |
| NCT03110445 | CancerTestis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus | View | |
| NCT03288623 | The Effects of Dark Chocolate Implementation in Elite Athletes | View | |
| NCT03329950 | A Study of CDX-1140 CD40 as Monotherapy or in Combination in Patients With Advanced Malignancies | View | |
| NCT03597282 | A Personal Cancer Vaccine NEO-PV-01 and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | View | |
| NCT03663335 | Study of Efficacy Safety Tolerability Pharmacokinetic PK and Pharmacodynamic PD of an Anti-CD40 Monoclonal Antibody CFZ533 in Kidney Transplant Recipients | View |